-
-
Overview
-
Tobramycin Sulfate, USP is an aminoglycoside antibiotic derived from Streptomyces tenebrarius. Tobramycin is a member of a broad-spectrum antibiotic complex, nebramycin, that was originally isolated in 1967 by Eli Lilly and Company. The nebramycin complex was separated into various factors, with nebramycin factor 6 showing in vitro activity of clinical usefulness. Nebramycin factor 6 was subsequently designated tobramycin.
Tobramycin Sulfate is a bactericidal protein synthesis inhibitor, able to bind to the 16S rRNA of the 30S ribosomal subunit, inhibiting translocation, and eliciting miscoding of the proteins. Tobramycin Sulfate has also shown a disruptive effect on the outer membrane of Gram-negative bacteria at high concentrations.
Tobramycin Sulfate is active against Gram-negative bacteria and is frequently used to eliminate Pseudomonas aeruginosa causing cystic fibrosis. Tobramycin like other aminoglycosides can be used to treat Gram-positive bacteria, but other types of antibiotics are more potent and less toxic. Tobramycin shows activity against mycobacteria but is mostly ineffective against fungi and viruses. Tobramycin Sulfate is freely soluble in aqueous solution.Please contact us at for specific academic pricing.
Background
Following active transport into the cell, Tobramycin Sulfate binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, Tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation.
-
- Properties
- Applications
-
Overview